From: kristoff@NET.BIO.NET (Dave Kristofferson)
Newsgroups: bionet.sci-resources
Subject: NIH Guide, vol. 21, no. 45, pt. 2, 18 December 1992
Date: 17 Dec 92 02:44:05 GMT
Distribution: bionet


$$XID NIHGUIDE 19921218 V21N45 P2O2 ************************************
Ms. Helen Ling
Grants Management Specialist
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 649
Bethesda, MD  20892
Telephone:  (301) 496-7467

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance No. 93.849.  Awards are made under authorization of the
Public Health Service Act, Title IV, Part A (Public Law 78-410, as
amended by Public Law 99-158, 42 USC 241 and 285) and administered
under PHS grants policies and Federal Regulations 42 CFR 52 and 45
CFR Part 74.  This program is not subject to the intergovernmental
review requirements of Executive Order 12372 or Health Systems Agency
review.

$$R7 END ************************************************************

$$R8 BEGIN DK-93-21 FULL-TEXT ***************************************

UROLOGY RESEARCH CENTERS

NIH GUIDE, Volume 21, Number 45, December 18, 1992

RFA AVAILABLE:  DK-93-21

P.T. 04; K.W. 0785220, 1002004, 1002008, 0710070, 1002019, 0710030

National Institute of Diabetes and Digestive and Kidney Diseases
The National Cancer Institute

Letter of Intent Receipt Date:  March 8, 1993
Application Receipt Date:  April 9, 1993

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.
POTENTIAL APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN
INQUIRES, BELOW.

PURPOSE

This RFA invites investigators to submit research applications for
the George M. O'Brien Research Centers Program.  The emphases for
this program are threefold: (1) to attract new scientific expertise
into the study of the basic mechanisms of urological diseases and
disorders; (2) to encourage multidisciplinary research focused on the
causes of these diseases and disorders; and (3) to extend the
development of innovative clinical and epidemiologic studies of the
causes, therapy and possible prevention of urological diseases and
disorders.  In approaching the study of these disease processes, it
is anticipated that extensive collaboration will be required between
individuals in the clinical and basic sciences, including for example
investigators with training and expertise in cell biology, molecular
biology, immunology, genetics, epidemiology, biochemistry,
physiology, and pathology.  It is the express intent of the
announcement to attract new investigators not currently active in
this field and to explore new basic areas that may have clinical
research applications.  Individual institutions with both basic and
clinical research capabilities are invited to apply.
Interinstitutional collaborative research arrangements are also
appropriate and encouraged.  Coordination for such arrangements must
be evident and clearly meaningful and appropriate for the research
proposed.

The National Cancer Institute (NCI) plans to provide support for this
program in the area of prostate cancer.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Urology Research Centers, is related to the area of diabetes and
other chronic disabling conditions.  Potential applicants may obtain
a copy of "Healthy People 2000" (Full Report:  Stock No.
017-001-00474-0) or Healthy People 2000" (Summary Report:  Stock No.
017-001-00473-1) through the Superintendent of Documents, Government
Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic for-profit and non-profit
organizations, public and private, such as universities, colleges,
hospitals, laboratories, units of State and local governments, and
eligible agencies of the Federal government.  Foreign institutions
are not eligible to apply.  Minority individuals and women are
encouraged to submit as principal investigators.

MECHANISM OF SUPPORT

Support of this program will be through the National Institutes of
Health (NIH) specialized center (P50) award.  Responsibility for the
planning, direction, and execution of the proposed project will be
solely that of the applicant.  Except as otherwise stated in this
announcement, awards will be administered under PHS grants policy as
stated in the PHS Grants Policy Statement.

FUNDS AVAILABLE

The NCI and the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) expect to jointly award up to two center
grants (P50) in fiscal year 1993 for research into urologic
disorders.  The anticipated awards are for five years and are
contingent upon the availability of appropriated funds.  The total
amount of available funds to support this program is anticipated to
be no more than $1.5 million per year.  No applicant may request more
than $750,000 (including both direct and indirect costs) in total
costs in the initial budget period.  A standard escalation factor may
be used for subsequent budget periods.  The award date for these
grants will be September 30, 1993.

SPECIAL REQUIREMENTS

Successful applicants are expected to attend a yearly meeting of
Center Directors convened by the NIDDK.  Funds to support travel to
this meeting may be requested in the budget proposed for the center.

STUDY POPULATIONS

It is NIH policy that women and minorities must be included in
clinical study populations unless there is a good reason to exclude
them.  The study design must seek to identify any pertinent gender or
minority population differences.

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

For projects involving clinical research, NIH requires applicants to
give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations, a specific justification for his exclusion must be
provided.  Applications without such documentation will not be
accepted for review.

LETTER OF INTENT

Prospective applicants are asked to submit, by March 8, 1993, a
letter of intent that includes a descriptive title of the proposed
research, the name, address, and telephone number of the Principal
Investigator, the identities of other key personnel and participating
institutions, and the number and title of the RFA in response to
which the application may be submitted.

A letter of intent is not required, is not binding, and does not
enter into the review of subsequent applications.

The letter of intent is to be sent to:

Chief, Review Branch
Division of Extramural Activities
National Institutes of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 605
Bethesda, MD  20892
Telephone:  (301) 496-7083
FAX:  (301) 402-1277

APPLICATION PROCEDURES

The research grant application form PHS 398 (rev. 9/91) is to be used
in applying for these grants.  The form is available from most
institutional offices of sponsored research and from the Office of
Grants Inquiries, Division of Research Grants, National Institutes of
Health, 5333 Westbard Avenue, Room 449, Bethesda, Maryland 20892,
telephone (301) 496-7441.

The RFA label available in the application form must be affixed to
the bottom of the face page.  Detailed instructions on submission
procedures are described in the RFA.

REVIEW CONSIDERATIONS

Upon receipt, applications will be initially reviewed for
completeness and responsiveness.  Incomplete applications or
non-responsive applications will be returned to the applicant without
further consideration.

Those applications that are complete and responsive will be evaluated
in accordance with the usual NIH peer review procedures.  Following
this review, the applications will be given a secondary review by the
National Diabetes and Digestive and Kidney Diseases Advisory Council
and the National Cancer Advisory Board unless not recommended for
further consideration by the initial review group.

INQUIRIES

Written and telephone inquiries concerning this RFA are encouraged.

Inquiries regarding non-cancer programmatic issues and requests for
copies of the RFA may be directed to:

Ralph L. Bain, Ph.D.
Director, Centers Program
Division of Kidney, Urologic, and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 3A-05
Bethesda, MD  20892
Telephone:  (301) 496-7574

Inquiries regarding cancer related programmatic issues and requests
for the RFA may be directed to:

Andrew Chiarodo, Ph.D.
Chief, Organ Systems Coordinating Branch
Centers, Training, and Resources Program
Division of Cancer Biology, Diagnosis and Centers
National Cancer Institute
Executive Plaza North,  Suite 316
Bethesda, MD  20892
Telephone:  (301) 496-8528

Inquiries regarding fiscal matters may be directed to:

Ms. Helen Ling
Grants Management Specialist
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 649
Bethesda, MD  20892
Telephone:  (301) 496-7467

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance No. 93.849.  Awards are made under authorization of the
Public Health Service Act, Title IV, Part A (Public Law 78-410, as
amended by Public Law 99-158, 42 USC 241 and 285) and administered
under PHS grants policies and Federal Regulations 42 CFR 52 and 45
CFR Part 74.  This program is not subject to the intergovernmental
review requirements of Executive Order 12372 or Health Systems Agency
review.

$$R8 END ************************************************************

$$R9 BEGIN HL-93-11 FULL-TEXT ***************************************

ASTHMA CLINICAL RESEARCH NETWORK

NIH GUIDE, Volume 21, Number 45, December 18, 1992

RFA AVAILABLE:  HL-93-11-L

P.T. 34; K.W. 0715013, 0745070, 0755018

National Heart, Lung, and Blood Institute

Letter of Intent Receipt Date:  March 1, 1993
Application Receipt Date:  May 6, 1993

THE REQUEST FOR APPLICATIONS (RFA) ANNOUNCED IN THIS NOTICE CONTAINS
ESSENTIAL INFORMATION FOR THE PREPARATION OF AN APPLICATION.
POTENTIAL  APPLICANTS MAY OBTAIN THE RFA FROM THE CONTACT NAMED IN
INQUIRIES BELOW.

PURPOSE

The Division of Lung Diseases invites applications for four Clinical
Groups and one Data Coordinating Center to participate, with the
assistance of the National Heart, Lung, and Blood Institute (NHLBI),
in the establishment of a network of interactive asthma clinical
research groups designed to facilitate evaluation of novel treatment
methods and management strategies for asthma; and to rapidly
disseminate the findings from these clinical studies to the health
care community.  This RFA is to:  (1) provide a mechanism to
establish and maintain the infrastructure required to perform
multiple therapeutic trials of novel treatments and management
strategies for asthma using common protocols with the requisite
numbers of patients.  Support would be provided to maintain the
infrastructure with additional funds provided on a cost per patient
basis for conducting clinical protocols.  (2) Establish a Data
Coordinating Center for the network.  The solicitation is for five
years.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Asthma Clinical Research Network, is related to the priority areas of
chronic disabling conditions and clinical prevention services.
Potential applicants may obtain a copy of "Healthy People 2000" (Full
Report:  Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary
Report:  Stock No. 017-001-00473-1) through the Superintendent of
Documents, Government Printing Office, Washington, DC 20402-9325
(telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic, for-profit and non-profit
organizations, public and private, such as universities, colleges,
hospitals, laboratories, units of State and local governments, and
eligible agencies of the Federal government.  Foreign organizations
are not eligible to apply and domestic applications may not include
international components.  Applications from minority individuals and
women are encouraged.

MECHANISM OF SUPPORT

The administrative and funding mechanism to be used to undertake this
program will be a cooperative agreement (U01), an assistance
mechanism.  Under the cooperative agreement, the NIH assists,
supports, and/or stimulates and is substantially involved with
recipients in conducting a study by facilitating performance of the
effort in a "partner" role.  The anticipated award date is September
30, 1993.

FUNDS AVAILABLE

An estimated four awards for Clinical Groups and one award for a Data
Coordinating Center will be made under this RFA.  A maximum of about
$17.4 million (including direct and indirect costs) over a five-year
period will be awarded for the Clinical Groups and the Data
Coordinating Center.  Approximately $2.50 million will be available
for the first year, $3.5 million for the second year, $3.6 million
for the third year, $3.8 million the fourth year and $3.9 million for
the last year.  It is anticipated that the award for each Clinical
Group will be about $475,000 total costs for the first year and the
award for the Data Coordinating Center will be about $600,000 total
costs for the first year.  Because the nature and scope of the
research proposed in response to this RFA may vary, it is anticipated
that the size of an award will also vary in all years.  Future year
costs will be distributed based on the recommended protocols.

At this time the NHLBI anticipates that there will be a renewed
competition after five years.  However, the final decision will
depend upon experience with the network during the first five years
as well as financial considerations.

RESEARCH OBJECTIVES

Asthma is an increasingly serious cause of morbidity and mortality in
the United States.  There are approximately 12 million asthmatics in
this country.  The disease affects both sexes and impacts all
racial/ethnic groups.  Despite major advances in understanding the
etiology and pathophysiology of asthma and the development of new
therapeutic modalities, the prevalence, severity, and mortality from
asthma have increased over the past decade in all age groups.  In
addition to the rise in morbidity and mortality, hospitalizations for
asthma have doubled in adults and increased fivefold for children
over the past 20 years.  Mortality rates appear to be particularly
high in urban and rural minority populations.  Asthma continues to
place a heavy burden on patients and their families, the health care
system, and society as a whole.  Therefore, new approaches are needed
to help alleviate this growing problem.

One important need is to establish a mechanism to allow rapid
evaluation of new and existing therapeutic approaches for asthma, and
for dissemination of laboratory and clinical findings to the health
care community.  This program seeks to accomplish this through a
network of interactive asthma clinical groups that conduct clinical
research in a coordinated and multidisciplinary setting.

The objective of this initiative is to establish a network of
interactive asthma clinical research groups to rapidly assess novel
treatment methods, and to ensure that these findings on optimal
management of asthmatic patients are rapidly disseminated to
practitioners and health care professionals.  This program is
intended to provide a mechanism to establish and maintain the
required infrastructure to perform multiple therapeutic trials in
asthmatic patients.  It is envisioned that the Clinical Groups would
have significant experience and a strong history of basic and
clinical research on the pathogenesis and treatment of asthma, since
the program infrastructure should be built around existing research
projects.  Therefore, it will be advantageous for groups to have had
substantial previous basic and/or clinical research experience in
asthma and asthma related fields.

The study population is envisioned to be asthmatic patients
encompassing a broad range of age groups and consisting of
appropriate gender and minority representation with clearly defined
and documented asthma.  At a minimum, one third of the patient
population at each clinic should be minority individuals and one half
women.  It is expected that each Clinical Group will have the ability
to access at least 400 patients for various protocols over the five
year period, but it is not envisioned that all 400 patients would
necessarily be enrolled in research protocols at any one time, and it
is possible that an individual patient may be involved in more than
one study.  Of the total patients accessible, investigators should
include substantial numbers from a broad age range, as well as a
description of the age distribution, and characteristics of the
population that they might recruit into potential clinical trials.

The overall population to be studied should provide data that are
broadly applicable to diverse minority groups as well as whites;
thus, the composition of the study population in this RFA program
must reflect this diversity.

The timetable for the network may be roughly subdivided into three
phases over a five year period.  Phase I consists of the first twelve
months and may be devoted to planning, development of the network
infrastructure, and protocol development.  In Phase II, protocol
development continues, patient recruitment and protocol
implementation are estimated to proceed over a 48-month period.
Phase III will consist of data analysis, report preparation, closeout
of the initial studies, further protocol development, continued
recruitment for the next studies, which may proceed over
approximately a 36-month period.

STUDY POPULATIONS

SPECIAL INSTRUCTIONS FOR INCLUSION OF WOMEN AND MINORITIES IN
CLINICAL RESEARCH STUDIES

For projects involving clinical research, the NIH requires applicants
to give special attention to the inclusion of women and minorities in
study populations.  If women or minorities are not included in the
study populations for clinical studies, a specific justification for
this exclusion must be provided. Applications without such
documentation will not be accepted for review.

LETTER OF INTENT

Prospective applicants are asked to submit, by March 1, 1993, a
letter of intent that includes a descriptive title of the proposed
research, the name, address, and telephone number of the Principal
Investigator, the identities of other key personnel and participating
institutions, and the number and title of the RFA in response to
which the application may be submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of subsequent applications, the information
that it contains is helpful in planning for the review of
applications.  It allows NHLBI staff to estimate the potential review
workload and to avoid conflict of interest in the review.

The letter of intent is to be sent to Dr. C. James Scheirer at the
address listed under INQUIRIES.

APPLICATION PROCEDURES

The research grant application form PHS 398 (rev. 9/91) is to be used
in applying for these grants.  These forms are available at most
institutional offices of sponsored research; from the Office of
Grants Inquiries, Division of Research Grants, National Institutes of
Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone
(301) 496-7441; and from the NIH Project Scientist named below.

Applications must be received by May 6, 1993.  If an application is
received after this date it will be returned to the applicant without
review.

REVIEW CONSIDERATIONS

Applicants are encouraged to submit and describe their own ideas on
how best to meet the goals of the study, but they are expected to
address issues identified under SPECIAL REQUIREMENTS of the RFA.
Note that this document is not the RFA.  Applications will be judged
primarily on the scientific quality of the application.  Although the
technical merit of the protocol is important, it will not be the sole
criterion for selection of a Clinical Group.  Other considerations
such as the importance and timeliness of the proposed clinical
trials, access to patients, multidisciplinary nature of the study,
the discussion of considerations relevant to this RFA, expertise of
the investigators, their capability to perform the work proposed, and
a demonstrated willingness to work as part of the network and with
the NHLBI Project Scientist will be part of the evaluation criteria.

The review group will assess (as further detailed in the RFA):

Clinical Groups

o  Scientific merit of the proposed clinical trials.

o  Qualifications, experience, and commitment of key personnel,
including their previous experience conducting clinical research in
asthma.

o  Plans to recruit an adequate number of patients, including
appropriate representation of minorities and women.

o  Facilities, equipment and organizational structure to effectively
implement protocols through the network.

o  Rationale and cost-effectiveness of the research approach
proposed.

Data Coordinating Center

o  Scientific merit of the proposed clinical trials.

o  Organizational, administrative, and supervisory ability and
statistical expertise to serve as a Data Coordinating Center for
multiple multicenter randomized controlled clinical trials in asthma.

o  Qualifications, experience, and commitment of key personnel.

o  Facilities and equipment to function as a Data Coordinating Center
for a multicenter network.

o  Appropriateness of the budget for the work proposed.

AWARD CRITERIA

Applications recommended by the National Heart, Lung, and Blood
Advisory Council will be considered for award based upon (a)
scientific and technical merit, importance of the proposed clinical
trials, timeliness, multidisciplinary nature of the study, and the
requirements explicitly stated in this RFA; (b) program balance,
including in this instance, sufficient compatibility of features to
make a successful collaborative program a reasonable likelihood; and
(c) availability of funds.

Letter of Intent:          March 1, 1993
Application Receipt Date:  May 6, 1993
Review by NHLBAC:          September 1993
Anticipated Award Date:    September 30, 1993

INQUIRIES

Written and telephone inquiries are encouraged.  The opportunity to
clarify any issues or questions from potential applicants is welcome.

Inquiries regarding this announcement and requests for the RFA may be
directed to:

James P. Kiley, Ph.D.
Division of Lung Diseases
National Heart, Lung, and Blood Institute
Westwood Building, Room 6A15
Bethesda, MD  20892
Telephone:  (301) 496-7332
FAX:  (301) 496-9886

Inquiries regarding review and application procedures may be directed
to:

C. James Scheirer, Ph.D.
Review Branch, Division of Extramural Affairs
National Heart, Lung, and Blood Institute
Westwood Building, Room 648
Bethesda, MD  20892
Telephone:  (301) 496-7363
FAX:  (301) 402-1660

Inquiries regarding fiscal and administrative matters may be directed
to:

Mr. Raymond L. Zimmerman
Grants Operations Branch
Division of Extramural Affairs
National Heart, Lung, and Blood Institute
Westwood Building, Room 4A11C
Bethesda, MD  20892
Telephone:  (301) 496-4970
FAX:  (301) 402-1200

AUTHORITY AND REGULATIONS

This project is described in the Catalog of Federal Domestic
Assistance No. 93.837.  Awards are made under authorization of the
Public Health Service Act, Title IV, Part A (Public Law 78-410, as
amended by Public Law 99-158, 42 USC 241 and 285) and administered
under PHS grants policies and Federal Regulations 42 CFR 52 and 45
CFR 74.  This project is not subject to the intergovernmental review
requirements of Executive Order 12372 or Health Systems Agency
review.

$$R9 END ************************************************************

                    ONGOING PROGRAM ANNOUNCEMENTS

$$P1 BEGIN PAR-93-33 ************************************************

NATIONAL CANCER INSTITUTE/MINORITY ACCESS TO RESEARCH CAREERS SUMMER
TRAINING SUPPLEMENT

NIH GUIDE, Volume 21, Number 45, December 18, 1992

PAR NUMBER:  PAR-93-33

P.T. 34, FF; K.W. 0715035, 0720005

National Cancer Institute

Application Receipt Date:  February 1, 1993

PURPOSE

The Comprehensive Minority Biomedical Program (CMBP) of the Division
of the Extramural Activities (DEA), National Cancer Institute (NCI),
invites interested grantee institutions that have Minority Access to
Research Careers (MARC) grants to apply for CMBP support of MARC
scholars interested in obtaining laboratory research experience at
the NCI.  This program announcement will be reissued on an annual
basis.

The NCI, through a co-funding arrangement with the MARC program of
the National Institute of General Medical Sciences (NIGMS), provides
support for research training to minority individuals and
institutions and conference grant support to further address and
enhance the mission of the National Cancer Program.  The NCI/MARC
Summer Training Program is an extension of the co-funding process.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Health People 2000,"
a PHS-led national activity for setting priority areas.  This program
announcement, NCI/MARC Summer Training Supplement, is related to the
priority area of cancer research. Potential applicants may obtain a
copy of "Health People 2000" (Full Report:  Stock No.
017-001-00474-0) or (Summary Report:  Stock No. 017-001-00473-1)
through the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (telephone 202-783-3238).

ELIGIBILITY CRITERIA

All domestic institutions with active MARC research training grants
are eligible to apply.

MECHANISM OF SUPPORT

A MARC honors training grant (T34) to the academic institution
requesting support for a student will be administratively
supplemented.  Unless otherwise noted, all PHS and NIH grants
policies apply to applications received in response to this
announcement.

The supplement will provide the following:  (1) A subsistence of $300
per week ($3,000 for a maximum ten-week period), and (2) round-trip
transportation (from MARC student's academic institution to the
National Institutes of Health, Bethesda, Maryland, and return to
student's academic institution). Indirect costs may be awarded to the
institution for up to a maximum of eight percent of the direct costs.

RESEARCH OBJECTIVES

The purpose of this award is to increase research training
opportunities in the NCI for underrepresented minority scholars and
to increase the number of minority scholars entering cancer-related
research careers through the influence of short-term laboratory
training at the NCI.

APPLICATION PROCEDURES

The Principal Investigator must submit a letter, countersigned by an
authorizing official of the grantee institution, requesting support
of a student for short-term laboratory training at the NCI.  This
letter will constitute an application and must include the following:

o  A statement from the student that describes his/her research
interests and career objectives and a brief resume;

o  Two letters of recommendation;

o  A current official college/university transcript;

o  The student's selection of three NCI laboratory choices
prioritized by level of interest;

o  The title of the announcement;

o  A copy of the face page of the active MARC grant including the
grant number and period of award; and

o  A description of the personnel to which the student will report
his/her NCI laboratory experience.

A list of NCI laboratory choices will be available to all applicants
through the CMBP office.

Application packages must be received by the CMBP no later than
February 1, 1993.

The 10-week training period may be between May 1993 and August 1993,
inclusive.  Under this announcement funding is available for this
period only.

More than one supplemental application may be submitted by each
grantee institution.

Supplemental applications to active MARC undergraduate training
grants must be submitted directly to the CMBP, with a copy to the
MARC program, at the address listed below.

REVIEW CONSIDERATIONS

Applications in response to this announcement will be considered by
NCI Staff; final selection for laboratory experience will be made by
the relevant laboratory directors.  Selection will be made on the
following criteria:

o  The strength of the interest in pursuing a laboratory experience
in the biomedical sciences based on the statement from the student;

o  The strength of the letters of recommendation;

o  Cumulative grade point average (2.75 or more based on 4.0
maximum).

Applications found to be responsive to the announcement will be
considered; those found to be unresponsive will not be considered.  A
letter from the CMBP Director will be sent to the grantee institution
stating the reason for the outcome of the evaluation.

INQUIRIES

Direct inquiries regarding programmatic issues to:

Program Director
Comprehensive Minority Biomedical Program
Division of Extramural Activities
National Cancer Institute
Building 31, Room 10A04
Bethesda, MD  20892
Telephone:  (301) 496-7344

Program Director
Minority Access to Research Careers
National Institute of General Medical Sciences
Westwood Building, Room 9A18
Bethesda, MD  20892
Telephone:  (301) 496-7941

Direct inquiries regarding fiscal matters to:

Ms. Carolyn Mason
Grants Management Specialist
Grants Administration Branch
National Cancer Institute
Executive Plaza South, Room 243
Bethesda, MD  20892
Telephone:  (301) 496-7800, Extension 59

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance, No. 93.398 Cancer Research Manpower.  National Institutes
of Health, Public Health Service, Department of Health and Human
Services Authorization:  Public Health Service Act, Service 413, as
amended by Public Law 99-158, 42 U.S.C. 288. Federal Agency:
National Institutes of Health, Public Health Service, Department of
Health and Human Service Authorization: Public Health Service Act,
Section 301, Public Law 78- 410, 42 U.S.C. 241, and Section 412, as
amended by Public Law 99.158, 42 U.S.C. 285a-1.  Executive Order
12372 applicable.

$$P1 END ************************************************************

                               ERRATUM

$$E1 BEGIN P2 19921120 APPEND PA-93-22 BOTH ****************************

"FAILURE TO THRIVE" SYNDROME AMONG OLDER PERSONS

NIH GUIDE, Volume 21, Number 45, December 18, 1992

PA NUMBER:  PA-93-22

P.T. 34; K.W. 0710010, 0710095, 0715072, 0710070, 0765035

National Institute on Aging
National Institute of Mental Health

This erratum is issued for Program Announcement PA-93-22, published
in the NIH Guide for Grants and Contracts, Vol. 21, No. 42, November
20, 1992.  There are two staff changes under the section INQUIRIES.

INQUIRIES

James K. Cooper, M.D., Geriatrics Program, Suite 3E327
Telephone:  (301) 496-6761

Pamela Starke-Reed, Ph.D., Biology of Aging Program, Suite 2C231
Telephone:  (301) 496-6402

$$E1 END ************************************************************


$$XID RFA DK9309 DK-93-09 P1O1 *****************************************

KIDNEY RESEARCH CENTERS

NIH GUIDE, Volume 21, Number 44, December 11, 1992

RFA:  DK-93-09

P.T. 04; K.W. 0785095, 1002004, 1002008, 0710070, 1002019, 0710030

National Institute of Diabetes and Digestive and Kidney Diseases

Letter of Intent Receipt Date:  March 8, 1993
Application Receipt Date:  April 9, 1993

PURPOSE

This Reques for Applications (RFA) invites investigators to submit
research applications for the George M. O'Brien Research Centers
Program.  The emphases for this program are threefold: (1) to attract
new scientific expertise into the study of the basic mechanisms of
kidney diseases and disorders; (2) to encourage multidisciplinary
research focused on the causes of these diseases; and (3) to extend
the development of innovative clinical and epidemiologic studies of
the causes, therapy, and possible prevention of kidney diseases and
disorders.  In approaching the study of these disease processes, it
is anticipated that extensive collaboration will be required between
individuals in the clinical and basic sciences, including, for
example, investigators with training and expertise in cell biology,
molecular biology, immunology, genetics, epidemiology, biochemistry,
physiology, and pathology.  It is the express intent of this
announcement to attract new investigators not currently active in
this field and to explore new basic areas that may have clinical
research applications.  Individual institutions with both basic and
clinical research capabilities are invited to apply.
Interinstitutional collaborative research arrangements are also
appropriate and encouraged.  Coordination for such arrangements must
be evident and clearly meaningful and appropriate for the research
proposed.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas.  This RFA,
Kidney Research Centers, is related to the area of diabetes and other
chronic disabling conditions.  Potential applicants may obtain a copy
of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or
"Healthy People 2000" (Summary Report:  Stock No. 017-001-00473-1)
through the Superintendent of Documents, Government Printing Office,
Washington, DC 20402-9325 (telephone 202-783-3238).

ELIGIBILITY REQUIREMENTS

Applications may be submitted by domestic for-profit and non-profit
organizations, public and private, such as universities, colleges,
hospitals, laboratories, units of State and local governments, and
eligible agencies of the Federal government.  Foreign institutions
are not eligible to apply.  Minority individuals and women are
encouraged to submit as Principal Investigators.

MECHANISM OF SUPPORT

Support of this program will be through the National Institutes of
Health (NIH) specialized center (P50) award.  Responsibility for the
planning, direction, and execution of the proposed project will be
solely that of the applicant.  Except as otherwise stated in this
announcement, awards will be administered under PHS grants policy as
stated in the PHS Grants Policy Statement.

FUNDS AVAILABLE

The National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) expects to award up to two center grants (P50) in FY 1993 for
research into kidney disorders.  The anticipated awards will be for
five years and will be contingent upon the availability of
appropriated funds.  The total amount of available funds to support
this program is anticipated to be no more than $1.5 million per year.
No applicant may request more than $750,000 in total costs (including
both direct and indirect costs) in the initial budget period.  A
standard escalation factor may be used for subsequent budget periods.
The award date for these grants will be September 30, 1993.

RESEARCH OBJECTIVES

Kidney diseases and disorders place a substantial burden on
individuals and on society in the United States.  They threaten the
health, well-being, and longevity of millions of Americans.  Chronic
renal failure, for example, accounted for an estimated $3.7 billion
of direct hospital and physican costs in 1990.  Although considerable
progress has been made in understanding the basic physiology and
pathophysiology of the normal renal systems, there has been only
limited progress in unraveling the mechanisms of those processes that
lead to progressive deterioration in the function of these systems.
Nevertheless, major progress has been made in the management of their
clinical consequences.  For example, renal dialysis and
transplantation are life saving procedures.  Unfortunately, these
scientific and medical advances have not led to the means to prevent
or reverse the consequences of these diseases and disorders; moreover
their incidence is steadily increasing.  The proposed
multidisciplinary research centers should help to provide an
environment for investigators to apply the necessary and appropriate
expertise to topical areas of research related to the pathogenesis of
kidney diseases such as:  immunologically mediated diseases; diabetes
mellitus and other endocrine and metabolic disorders; primary renal
hypertension; genetic abnormalities; and nephrotoxins and toxic cell
injury.

Applicants from institutions that have a General Clinical Research
Center (GCRC) funded by the NIH National Center for Research
Resources may wish to identify the GCRC as a resource for conducting
the proposed research.  If so, a letter of agreement from either the
GCRC program director or Principal Investigator may be included with
the application.

SPECIAL REQUIREMENTS

Successful applicants are expected to attend a yearly meeting of
Center Directors convened by the NIDDK.  Funds to support travel to
this meeting may be requested in the budget proposed for the center.

STUDY POPULATIONS

It is NIH policy that women and minorities must be included in
clinical study populations unless there is a good reason to exclude
them.  The study design must seek to identify any pertinent gender or
minority population differences.

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

NIH policy is that applicants for NIH clinical research grants and
cooperative agreements are required to include minorities and women
in study populations so that research findings can be of benefit to
all persons at risk of the disease, disorder or condition under
study; special emphasis must be placed on the need for inclusion of
minorities and women in studies of diseases, disorders and conditions
which disproportionately affect them.  This policy is intended to
apply to males and females of all ages.  If women or minorities are
excluded or inadequately represented in clinical research,
particularly in proposed population-based studies, a clear compelling
rationale must be provided.

The composition of the proposed study population must be described in
terms of gender and racial/ethnic group.  In addition, gender and
racial/ethnic issues must be addressed in developing a research
design and sample size appropriate for the scientific objectives of
the study.  This information must be included in the form PHS 398
(rev. 9/91) in Item 4 (Research Design and Methods) of the Research
Plan AND summarized in Item 5, Human Subjects.  Applicants are urged
to assess carefully the feasibility of including the broadest
possible representation of minority groups.  However, NIH recognizes
that it may not be feasible or appropriate in all research projects
to include representation of the full array of United States
racial/ethnic minority populations; i.e., Native Americans [including
American Indians or Alaskan Natives], Asian/Pacific Islanders,
Blacks, Hispanics.

The rationale for studies on single minority population groups should
be provided.

For the purpose of this policy, clinical research is defined as human
biomedical and behavioral studies of etiology, epidemiology,
prevention [and preventive strategies], diagnosis, or treatment of
diseases, disorders or conditions, including but not limited to
clinical trials.

The usual NIH policies concerning research on human subjects also
apply.  Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded.  However,
every effort should be made to include human tissues from women and
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.

If the required information is not contained within the application,
the application will be returned without review.

Peer reviewers will address specifically whether the research plan in
the application conforms to these policies.  If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the
selected study population is inadequate, it will be considered a
scientific weakness or deficiency in the study design and reflected
in assigning the priority score to the application.

All applications for clinical research submitted to NIH are required
to address these policies.  NIH funding components will not award
grants or cooperative agreements that do not comply with these
policies.

LETTER OF INTENT

Prospective applicants are asked to submit, by March 8, 1993, a
letter of intent that includes a descriptive title of the proposed
research, the name, address, and telephone number of the Principal
Investigator, the identities of other key personnel and participating
institutions, and the number and title of the RFA in response to
which the application may be submitted.

Although a letter of intent is not required, is not binding, and does
not enter into the review of subsequent applications, the information
that it contains is helpful in planning for the review of
applications.  It allows NIDDK staff to estimate the potential review
workload and to avoid possible conflict of interest in the review.

The letter of intent is to be sent to:

Chief, Review Branch, Division of Extramural Activities
National Institute of Daibetes and Digestive and Kidney Diseases
Westwood Building, Room 605
5333 Westbard Avenue
Bethesda, MD  20892
Telephone:  (301) 496-7083
FAX:  (301) 402-1277

APPLICATION PROCEDURES

The research grant application form PHS-398 (rev. 9/91) is to be used
in applying for these grants.  The form is available from most
institutional offices of sponsored research and from the Office of
Grants Inquiries, Division of Research Grants, National Institutes of
Health, 5333 Westbard Avenue, Room 449, Bethesda, MD 20892, telephone
(301) 496-7441.

The RFA label available in the application form must be affixed to
the bottom of the face page.  Failure to use this label could result
in delayed processing of the application such that it may not reach
the review committee in time for review.  In addition, the RFA title
and number must be typed on line 2a of the face page of the
application form and check the YES box.

Applications must include the following items:

o  A Table of Contents;

o  A Rationale for the proposed Center and a Statement of Objectives;

o  Institutional Environment and Resources;

o  Organization and Administrative Structure of the Center;

o  Specific Managerial Responsibilities for the Center;

o  Travel funds in the proposed budget for an annual meeting of
Center Directors;

o  A description of the method for the replacement of the Center
Director (should the need arise);

o  A description of the proposed research projects;

o  A description of the proposed cores;

o  A description of the procedure to be used for the
addition/deletion of cores and projects during the proposed period of
operation;

o  A description of the administrative relationship of the Center to
the applicant institution.

Submit a signed, typewritten original of the application, including
the Checklist, and three signed, exact photocopies, in one package
to:

Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD  20892**

At time of submission, two additional copies of the application must
also be sent under separate cover to:

Chief, Review Branch, Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 605
5333 Westbard Avenue
Bethesda, MD  20892

Applications must be received by April 9, 1993.  If an application is
received after that date, it will be returned to the applicant.

REVIEW CONSIDERATIONS

Upon receipt, applications will be initially reviewed for
completeness and responsiveness.  Incomplete applications or
non-responsive applications will be returned to the applicant without
further consideration.  Evaluation for responsiveness to the program
requirements and criteria stated in the RFA is an NIDDK staff
function.

Those applications that are complete and responsive will be evaluated
in accordance with the criteria stated below for scientific/technical
merit by an appropriate peer review group convened by the NIDDK.

If the number of applications is large compared to the number of
awards to be made, a preliminary scientific peer review may be
conducted and applications withdrawn from further competition when
they are not competitive for the award.  The NIDDK will notify the
applicant and institutional official of this action. Those
applications judged to be competitive will be reviewed for scientific
and technical merit in accordance with the usual NIH peer review
procedures by an initial review group specifically convened for this
RFA.

Following this review, the applications will be given a secondary
review by the NIDDK Advisory Council unless not recommended for
further consideration by the initial review group.

The review criteria for individual research projects include:

o  The scientific, technical or medical significance and originality
of the proposed research;

o  The feasibility and adequacy of the experimental design(s);

o  The qualifications and research experience of the proposed
personnel;

o  The availability of resources necessary for the research;

o  The appropriateness of the budget and timetable in relation to the
scope of the proposed research;

The review criteria for scientific cores include:

o  The appropriateness and utility of the core to the proposed
Center;

o  Each core unit must provide facilities or services to at least two
research projects recommended for approval;

o  The quality of the proposed facilities or services including
administrative arrangements for utilizing the core;

o  The qualifications, experience, and commitment of the personnel
involved in the core;

o  The appropriateness of the budget.

The review criteria for the overall Center program include:

o  The scientific merit of the program as a whole;

o  The significance of the overall goals of the Center;

o  The cohesiveness and multidisciplinary scope of the Center and the
coordination and interrelationship of the projects and cores to the
common theme of the Center;

o  The leadership, scientific expertise, and commitment of the
proposed Center Director.

Administrative Considerations:

o  The institutional environment for and resources available to
Center investigators;

o  The institutional commitment to the proposed Center;

o  The administrative leadership necessary to provide for the quality
control of supported projects in the Center, the allocation of funds,
and the ability to foster communication and cooperation among Center
investigators;

o  The appropriateness of the budget in relation to the proposed
activities of the Center;

o  The adequacy of addressing the protection of human subjects,
animal welfare, and biohazard issues.

AWARD CRITERIA

The anticipated date of award is September 30, 1993.  Factors that
will be taken into consideration in making awards include the
scientific merit of the proposed Center as determined by peer review
and the availability of funds.

Schedule

Letter of Intent:     March 8, 1993
Application Receipt:  April 9, 1993
Initial Review:       July 1993
Second Level Review:  September 13-14, 1993
Anticipated Award:    September 30, 1993

INQUIRIES

Written and telephone inquiries concerning this RFA are encouraged.

Inquiries regarding programmatic issues may be directed to:

Ralph L. Bain, Ph.D.
Director, Centers Program
Division of Kidney, Urologic, and Hematologic Diseases
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 3A-05
Bethesda, MD  20892
Telephone:  (301) 496-7574

Inquiries regarding fiscal matters should be directed to:

Ms. Helen Ling
Division of Extramural Activities
National Institute of Diabetes and Digestive and Kidney Diseases
Westwood Building, Room 649
5333 Westbard Avenue
Bethesda, MD  20892
Telephone:  (301) 496-7467

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance No. 93.849.  Awards are made under authorization of the
Public Health Service Act, Title IV, Part A (Public Law 78-410, as
amended by Public Law 99-158, 42 USC 241 and 285) and administered
under PHS grants policies and Federal Regulations 42 CFR 52 and 45
CFR Part 74.  This program is not subject to the intergovernmental
review requirements of Executive Order 12372 or Health Systems Agency
review.